Author(s):
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer
Email(s):
rehan_haider64@yahoo.com , drasgharmehdi@gmail.com , dasgeetha342@gmail.com , ahmed_dr2003@yahoo.com , sambreenzameer@yahoo.com
DOI:
10.52711/2231-5691.2025.00039 
Address:
Rehan Haider1, Asghar Mehdi2, Geetha Kumari Das3, Zameer Ahmed4, Sambreen Zameer5
1PhD Riggs Pharmaceuticals Department of Pharmacy, University of Karachi, Pakistan.
2PhD Head Department of Pharmacology, Fazaia Ruth Pfau Medical College Air University Karachi, Pakistan.
3Ph.D GD Pharmaceutical Inc OPJS University, Rajasthan, India.
4PhD Assistant Professor Dow University of Health Sciences, Karachi, Pakistan.
5Associate Professor, Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2025
ABSTRACT:
Rabies continues to pose a critical danger to international public health, highlighting the want for greater powerful vaccines. This takes a look at the specialty of the development of rabies virus-like particles (RVLPs) as a novel vaccine candidate. RVLPs were successfully produced using a recombinant baculovirus expression system in insect cells, which allowed for high yield and scalability. certain characterization via electron microscopy, dynamic mild scattering, and Western blotting confirmed that RVLPs closely mimic the morphology and antigenicity of the native rabies virus. In vitro experiments confirmed that RVLPs prompted a sturdy immune reaction, as indicated via high levels of neutralizing antibodies. In vivo protection studies carried out in a mouse version revealed that vaccination with RVLPs supplied entire safety towards a lethal Rabies virus venture, demonstrating their potential as a powerful vaccine. moreover, RVLPs showed a positive protection profile, and no damaging effects were determined. The findings from those production, characterization, and safety studies advise that RVLPs ought to appreciably beautify the efficacy and protection of rabies vaccines. destiny research needs to goal at optimizing large-scale manufacturing and accomplishing clinical trials to affirm the efficacy and safety of RVLPs in people.
Cite this article:
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer. Development of Rabies Virus-Like particles for Vaccine applications: Production, Characterization, and protection Studies. Asian Journal of Pharmaceutical Research. 2025; 15(3):241-8. doi: 10.52711/2231-5691.2025.00039
Cite(Electronic):
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer. Development of Rabies Virus-Like particles for Vaccine applications: Production, Characterization, and protection Studies. Asian Journal of Pharmaceutical Research. 2025; 15(3):241-8. doi: 10.52711/2231-5691.2025.00039 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2025-15-3-3
REFERENCES:
1. Yousaf MZ, Qasim M, Zia S, Khan MR, Ashfaq UA, Khan S. Rabies molecular virology, diagnosis, prevention and treatment. Virol J. 2012; 9: 50
2. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The mobile biology of rabies virus: the usage of stealth to attain the brain. Nat Rev Microbiol. 2010; 8: 51–61
3. Gautret P, Parola P. Rabies vaccination for global travelers. Vaccine. 2012; 30: 126–133
4. Meslin FX, Briggs DJ. Getting rid of dog rabies, the most important source of human contamination: what's going to it take? Antivir Res. 2013; 98: 291–296
5. World Health Organisation. WHO expert session on rabies. 2nd document. World Health Organ Tech Rep Ser. 2013; 982
6. Ertl HC. Novel vaccines to human rabies. PLoS Negl Trop Dis. 2009; 3(9): 515
7. Yang DK, Kim HH, Lee KW, Song JY. The existence and destiny of rabies vaccine in animals. Clin Exp Vaccine Res. 2013; 2: 19–25
8. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003; 11: 438–444
9. Roldão A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM. Virus-like debris in vaccine improvement. Professional. Rev Vaccines. 2010; 9(10): 1149–1176
10. Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014; 111: 425–440
11. Fontana D, Kratje R, Etcheverrigaray M, Prieto C. Rabies virus-like particles expressed in HEK293 cells. Vaccine. 2014; 32: 2799–2804
12. Wu CY, YehYC YYC, Chou C, Liu MT, Wu HS, Chan JT, Hsiao PW. Mammalian expression of virus-like particles for advanced mimicry of genuine influenza virus. Plos. 2010; 15(3): e784
13. Chuan Li C, Liu F, Liang M, Zhang Q, Wang X, Wang T, Li J, Li D. Hantavirus-like particles generated in CHO cells set off specific immune responses in C57BL/6 mice. Vaccine. 2010; 28:4294–4300
14. Hua RH, Li YN, Chen ZS, Liu LK et al. generation and characterization of a new mammalian cell line continuously expressing virus-like particles of eastern encephalitis virus for a subunit vaccine candidate. BMC Biotechnol. 2014; 14: 62
15. dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A 0.33-generation lentivirus vector with a conventional packaging gadget. J Virol. 1998; 72: 8463–8471
16. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene shipping and strong transduction of nondividing cells by a lentiviral vector. Science. 1996; 272: 263–267
17. Picanço-Castro V, Fontes AM, de Sousa Russo- Carbolante EM, Covas DR. Lentiviral- mediated gene switch – a patent review. Professional Opin Ther Pat. 2008; 18(5): 1–15
18. Federico M (ed). Lentivirus gene engineering protocols. 2nd version. Strategies in Molecular Biology, Vol. 614. Humana, United Kingdom. 2010
19. Zeltins A. Creation and individualization of virus-like debris: an overview. Mol Biotechnol. 2012; 53: 92–107
20. Wilbur L. A., Aubert MFA. The NIH efficiency check. In: Meslin FX, Kaplan MM. Koprowsky H (Eds) Laboratory strategies in rabies. WHO, Geneva, Switzerland. 1996: 360–366
21. Prieto C, Fontana D, Etcheverrigaray M, Kratje R. A strategy to obtain recombinant cellular traces with excessive expression stages. Lentiviral vector-mediated transgenesis. BMC Proc. 2011; 5(8): P7